Proglumetacin (protacine) : a promising new treatment of the rheumatic joint
Twenty-three out-patients with rheumatic disorders were treated over a period of 3 weeks with 450 mg proglumetacin per day, in two divided doses. Articular pain significantly decreased by 57% during the first week, and by 85% in Week 3. This was the result of two actions: a decrease in the number of...
| Publié dans: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1982), 3 vom: 31., Seite 169-73 |
|---|---|
| Auteur principal: | |
| Format: | Article |
| Langue: | English |
| Publié: |
1982
|
| Accès à la collection: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC) |
| Sujets: | Journal Article Anti-Inflammatory Agents Indoleacetic Acids proglumetacin FV919079LU |
| Résumé: | Twenty-three out-patients with rheumatic disorders were treated over a period of 3 weeks with 450 mg proglumetacin per day, in two divided doses. Articular pain significantly decreased by 57% during the first week, and by 85% in Week 3. This was the result of two actions: a decrease in the number of painful joints, and in the intensity of pain in those still painful. The number of oedematous joints turned from swollen to normal in a proportion of 57% after 1 week and 87% after 3 weeks of treatment. These actions resulted in a significant recovery of mobility, expressed as both morning stiffness and hand grip strength. Erythrocyte sedimentation rate and rheumatoid factor titre also improved significantly. Proglumetacin was well-tolerated by all patients |
|---|---|
| Description: | Date Completed 18.12.1982 Date Revised 15.11.2012 published: Print Citation Status MEDLINE |